ESMO Virtual Congress 2020 Prostate Cancer

Viewing 1-20 of 66 articles

ESMO Virtual Congress 2020: Complex Biomarkers in Drug Development

ESMO Virtual Congress 2020: Clinical Factors That Are Prognostic for Survival Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223

ESMO Virtual Congress 2020: Darolutamide, Enzalutamide and Apalutamide the Risk of Adverse Events in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Number Needed to Harm

ESMO Virtual Congress 2020: Quality of Life and Survival in Elderly Metastatic Castration-Resistant Prostate Cancer Patients Treated with Docetaxel

ESMO Virtual Congress 2020: Real-World Patterns of Genomic Testing in Patients with Metastatic Castration-Resistant Prostate Cancer

ESMO Virtual Congress 2020: Pembrolizumab plus Docetaxel and Prednisone in Patients with Abiraterone Acetate– or Enzalutamide–Pretreated Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-365 Cohort B Update

ESMO Virtual Congress 2020: NRG Oncology’s GU007 (NADIR): Niraparib with Standard Combination with ADT and Radiotherapy in High-Risk Prostate Cancer

ESMO Virtual Congress 2020: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate (ANZUP 1801)

ESMO Virtual Congress 2020: Tumour-Only Sequencing Led to Inflated Tumour Mutational Burden Estimation Especially in Under-Represented Ethnic Groups

ESMO Virtual Congress 2020: Treatment in CARD Eligible Metastatic Castration Resistant Prostate Cancer Patients According to the Status of Germline HRR Mutations: Cabazitaxel vs Enzalutamide/Abiraterone

ESMO Virtual Congress 2020: Pan-Cancer Analysis of Homologous Recombination Associated Alterations and Genome-Wide Loss of Heterozygosity

ESMO Virtual Congress 2020: Invited Discussant: (617MO) Repurposing Metformin as Anticancer Drug (MANSMED) and (618MO) Local Therapy to the Primary Tumour for Newly Diagnosed, Oligo-Metastatic Prostate Cancer

ESMO Virtual Congress 2020: PROREPAIR-A Study Results: Clinical Impact of Somatic Alterations in Prostate Cancer Patients with and without Previously Known Germline BRCA1/2 Mutations

ESMO Virtual Congress 2020: Abiraterone Acetate plus Prednisolone for Hormone-Naïve Prostate Cancer: Long-Term Results from Metastatic (M1) Patients in the STAMPEDE Randomized Trial

ESMO Virtual Congress 2020: Invited Discussant: Abiraterone Acetate plus Prednisolone for Hormone-Naïve Prostate Cancer: Long-Term Results from Metastatic (M1) Patients in the STAMPEDE Randomised Trial

ESMO Virtual Congress 2020: Divergent Results Between Advanced Prostate Cancer Consensus Conference (APCCC) Panelist and Global Non-Panelist Survey Respondents

ESMO Virtual Congress 2020: Results of the PSMA/CD3 BiTE AMG 160 in the Context of Immunotherapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ESMO Virtual Congress 2020: Invited Discussant: Novel Therapeutic Strategies for Improving Outcomes in Men with Castration-Resistant Prostate Cancer

ESMO Virtual Congress 2020: Invited Discussant: DNA Damage Repair Alterations in the Management of Prostate Cancer

ESMO Virtual Congress 2020: A Phase 3, Randomized, Double-Blind Trial of Nivolumab or Placebo Combined with Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (CheckMate 7DX)

1
2
3
4